Biotech Acquisition Company Warrant
BIOTW
BIOTW was delisted on the 2nd of February, 2023.
39 hedge funds and large institutions have $6.51M invested in Biotech Acquisition Company Warrant in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
11% more funds holding
Funds holding: 35 → 39 (+4)
2% less capital invested
Capital invested by funds: $6.61M → $6.51M (-$103K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRCM
Sage Rock Capital Management
New York
|
+$213K |
| 2 |
RA
Ramius Advisors
New York
|
+$90.8K |
| 3 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$83.7K |
| 4 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
+$74.4K |
| 5 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$55.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KSCM
Kamunting Street Capital Management
Miami Beach,
Florida
|
-$137K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$9.05K |
| 3 |
Jane Street
New York
|
-$660 |
| 4 |
EAM
Exos Asset Management
New York
|
-$69 |
BIOTW Hedge Fund Activity: Q3 2021 in Review
39 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q3 2021, worth a combined $6.51M — down 1.6% from $6.61M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BIOTW positions and 1 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Sage Rock Capital Management, opening a new position worth an estimated $213K. The largest seller was Kamunting Street Capital Management, exiting entirely with an estimated $137K sold.
- 39 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q3 2021, up from 35 in Q2 2021.
- Funds reported $6.51M of Biotech Acquisition Company Warrant stock for Q3 2021, down 1.6% quarter-over-quarter.
- 5 funds opened new Biotech Acquisition Company Warrant positions in Q3 2021 and 1 closed out, a net change of +4 holders.
- The largest Biotech Acquisition Company Warrant buyer in Q3 2021 was Sage Rock Capital Management, an estimated $213K added.
- The largest Biotech Acquisition Company Warrant seller in Q3 2021 was Kamunting Street Capital Management, an estimated $137K sold.
Based on aggregated 13F filings for Q3 2021.